United Therapeutics (UTHR) has released an update.
In a bold move, the Company has announced a lawsuit against the FDA regarding a dispute over Liquidia Technologies, Inc.’s attempt to expand the use of its treprostinil product for treating pulmonary hypertension in patients with interstitial lung disease. This legal battle could have significant implications for both companies and the pharmaceutical industry at large.
For further insights into UTHR stock, check out TipRanks’ Stock Analysis page.
